Hamada Yuki, Matsuoka Hideki, Sato Shinsuke, Kawabata Yutaro, Iwamoto Kana, Ikeda Mei, Sato Takeo, Takaguchi Go, Takashima Hiroshi
Department of Strokology, Stroke Center, National Hospital Organization Kagoshima Medical Center, Kagoshima, Japan.
Department of Neurosurgery, St. Luke's International Hospital, Tokyo, Japan.
Front Neurol. 2024 Aug 27;15:1424030. doi: 10.3389/fneur.2024.1424030. eCollection 2024.
Endovascular therapy (EVT) for distal medium vessel occlusions requires prioritizing effectiveness and safety. We developed a technique combining the deployment of only the distal basket segment of the EMBOTRAP III and an aspiration catheter (AC) for M2 occlusions, called the "ONE-SEG technique," and evaluated its clinical and technical impacts.
This was a retrospective review of 30 consecutive patients with M2 segment middle cerebral artery occlusion treated using the ONE-SEG technique. This method involves deploying the EMBOTRAP III through a microcatheter in only one segment and guiding the AC to the M2 origin or distal M1. The rates of final-pass expanded thrombolysis in cerebral infarction (eTICI) scores of 2c/3 or 2b/2c/3, safety (symptomatic intracranial hemorrhage [sICH]), and clinical outcomes (modified Rankin Scale [mRS] score 0-2, 0-3 at 90 days, and mortality at 90 days) were evaluated.
Of the 30 cases, 36.7% were female, and the mean age was 75.6 ± 11.0 years. The ONE-SEG technique was used for 17 cases (56.7%, median NIHSS 10 [5-15.5]) with primary M2 occlusion and 13 cases (43.3%, median NIHSS 20 [14-22.5]) with secondary M2 occlusion after proximal thrombus removal. The successful final reperfusion rate (eTICI 2b/2c/3) was 90% overall (27/30 cases). One case (3.3%) developed sICH with secondary M2 occlusion. At 3 months, mRS scores 0-2 were seen in 64.7% of patients with primary M2 occlusion (11/17 cases) and in 23.1% (3/13 cases) with secondary M2 occlusion.
EVT using the ONE-SEG technique appears to be safe and effective for M2 occlusion.
对于大脑中动脉远端中等血管闭塞的血管内治疗(EVT),需要兼顾有效性和安全性。我们研发了一种技术,即仅将EMBOTRAP III的远端网篮部分与用于M2段闭塞的抽吸导管(AC)联合使用,称为“单段技术”,并评估了其临床和技术影响。
这是一项对连续30例使用单段技术治疗大脑中动脉M2段闭塞患者的回顾性研究。该方法包括仅通过微导管在一个节段内植入EMBOTRAP III,并将AC引导至M2起始部或M1远端。评估最终再灌注率(脑梗死扩展溶栓(eTICI)评分达到2c/3或2b/2c/3)、安全性(症状性颅内出血[sICH])以及临床结局(改良Rankin量表[mRS]评分在90天时为0 - 2、0 - 3,90天时的死亡率)。
30例患者中,女性占36.7%,平均年龄为75.6 ± 11.0岁。单段技术用于17例(56.7%,美国国立卫生研究院卒中量表[NIHSS]中位数为10[5 - 15.5])原发性M2段闭塞患者,以及13例(43.3%,NIHSS中位数为20[14 - 22.5])近端血栓清除术后继发性M2段闭塞患者。总体成功的最终再灌注率(eTICI 2b/2c/3)为90%(27/30例)。1例(3.3%)继发性M2段闭塞患者发生了sICH。在3个月时,原发性M2段闭塞患者中64.7%(11/17例)的mRS评分为0 - 2,继发性M2段闭塞患者中23.1%(3/13例)的mRS评分为0 - 2。
使用单段技术进行EVT治疗M2段闭塞似乎是安全有效的。